Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 2/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918359 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL30290594 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL173595 | 1.00 | MAPK14 (1.00) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7767926 | 0.95 | MAPK14 (0.90) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7767982 | 0.92 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7773635 | 0.92 | MAPK14 (0.84) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL29706562 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7771968 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL7772134 | 0.91 | MAPK14 (0.83) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 | |
| SCHEMBL4916787 | 0.90 | MAPK14 (0.81) | MAPK14PRKD3MAP4K4PRKCACSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| WO-2023178169-A2 | COMPOSITIONS AND METHODS FOR TREATING THE PATHOPHYSIOLOGY OF SEVERE VIRAL INFECTION | ANEMOI BIOTECH HOLDINGS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| EP-3553169-B1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2021-11-03 | — | — | EP | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3111937-B1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-06-17 | — | — | EP | claimed |
| US-20170191038-A1 | TGFß SIGNALING INDEPENDENT NAÏVE INDUCED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USE | HONG GUAN LTD (CN) | 2017-07-06 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| EP-0889888-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2002060869-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATION-ENHANCED COUGH | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | claimed |
| US-6387898-B1 | USING IMIDAZOLE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-05-14 | — | — | US | claimed |
| WO-2002032862-A2 | USE OF P38 INHIBITORS FOR THE TREATMENT OF SMOKE INHALATION | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-25 | — | — | WO | claimed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| EP-0889726-A4 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885PRKD3 728/4885MAP4K4 69/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885PRKD3 813/4885MAP4K4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.